The pharmaceutical company Crucell, in collaboration with Harvard University, "plans to test its experimental AIDS vaccine in the U.S. and in Africa, advancing the quest for a protective shot against" HIV, Bloomberg reports. The trial will test the vaccine in uninfected adults "to assess its safety and ability to prompt an immune response ... the company said in a statement." Bloomberg continues, "The vaccine combines shots ... in a so-called prime-boost approach that's designed to both kill infected cells and prevent HIV from entering those that are uninfected" (Bennett, 8/11).
Back to other news for August 2010
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy